Introduction
For years the dogma in managing acute intracranial insults was to keep patients 'dry' to minimize brain edema. At times, this was accomplished at the expense of blood pressure and cerebral perfusion. The first challenge to this approach came in the 1970s and 1980s with the observation that hypovolemia was associated with cerebral infarction in patients with vasospasm following subarachnoid hemorrhage (SAH). At the same time measurements of cerebral blood flow (CBF) in patients with traumatic brain injury (TBI) demonstrated reduced blood flow, raising concern for ongoing ischemic damage. The next step, blood pressure augmentation, quickly followed based on several thoughts. Reduced cerebral perfusion pressure (CPP), due to intracranial hypertension or inadequate blood pressure, contributes to a fall in CBF in patients with severe TBI. Similarly, since vasospasm results in impaired regional perfusion, hemodynamic manipulation would improve it. Finally, impaired autoregulation raises the critical threshold for CPP.
Cerebral perfusion pressure, mean arterial pressure and cerebral blood flow CPP is the difference between the mean arterial pressure (MAP) and the downstream pressure, either jugular venous or intracranial pressure (ICP), whichever is higher. For patients without venous disease and normal ICP, it is essentially equal to the MAP. Increases in MAP will increase CPP, whereas reductions will lower it.
Effect of reducing cerebral perfusion pressure in the normal brain When CPP falls, the cerebral vasculature responds by dilating resistance arterioles in order to keep CBF constant, maintaining delivery of oxygen and nutrients. Conversely, when CPP rises, the resistance vessels constrict maintaining CBF at stable levels, a process called autoregulation [1] . Autoregulation operates over a wide range of perfusion pressures (between 50 and 150 mmHg in normotensive adults); its limits are determined by the extremes of vasoconstriction and vasodilation of the resistance arterioles [2] . When the lower limit of autoregulation is exceeded, CBF begins to fall. The brain responds to the fall in CBF by increasing oxygen extraction thus allowing preservation of normal cerebral oxygen metabolism [3] . The oxygen extraction fraction (OEF) can increase from a baseline of approximately 30-50% to over 80% (Fig. 1) .
Increase in oxygen extraction manifests as a widening of the arteriovenous difference of oxygen content (a-vDO 2 ) or a fall in jugular venous oxygen saturation. Increased OEF or widened a-vDO 2 are the markers of inadequate blood flow (oxygen delivery) relative to tissue needs (oxygen consumption) also known as flow-metabolic mismatch. Once both autoregulatory capacity and the OEF response have been exhausted, ischemia ensues and metabolic rate begins to fall. Depending on the degree and duration of ischemia, permanent tissue infarction will occur [4] .
Effect of reducing cerebral perfusion pressure in the injured brain
Autoregulatory function is frequently lost during ischemia [5] following severe TBI and during vasospasm following SAH [6] . In the setting of impaired autoregulation, a fall in perfusion pressure leads directly to a reduction in CBF [7] [8] [9] , and the CPP needed to prevent ischemia may be higher than normal. If perfusion pressure falls beyond the ability of OEF to compensate, ischemia ensues.
Rationale for hemodynamic augmentation in subarachnoid hemorrhage
The causes for reduced CBF and subsequent delayed ischemic deficits (DIDs) in patients with vasospasm are likely a result of some combination of three key factors: severe narrowing of the large intracranial arteries (leading to reduced perfusion pressure), intravascular volume depletion [10] [11] [12] and a loss of normal autoregulatory function in the distal circulation [13] [14] [15] . Increased ICP may play a role as well.
The term 'vasospasm' in the setting of SAH has several meanings. Narrowing develops in the large intracranial vessels seen on imaging and is referred to as 'angiographic vasospasm'. Large vessel narrowing can also be assessed by transcranial Doppler (TCD), which detects angiographic vasospasm with high sensitivity and low specificity. Finally, the appearance of clinical deficits is referred to as 'clinical vasospasm' or DID. With the onset of clinical symptoms, CBF has fallen so low that the compensatory rise in OEF can no longer maintain adequate oxygen delivery to meet the metabolic needs of the tissue [16] [17] [18] [19] . The presence of neurological deficits has been associated with regional CBF less than 20 ml/100 g/min in patients with SAH-induced vasospasm [18, 20] , similar to the values reported with ischemic stroke (23-27 ml/100 g/min). Permanent tissue infarction may result depending on the degree and duration of ischemia [4] .
The mechanisms responsible for large artery narrowing seen on angiography have not been completely elucidated; however, a considerable body of evidence points to the presence of erythrocytes and erythrocyte breakdown products. Oxyhemoglobin, particularly, has been found on the abluminal side of the vessel as the initiating factor [21, 22] . A correlation between the thickness of subarachnoid clot and the development and severity of subsequent vasospasm has been repeatedly observed [23 ,24] .
Angiographic evidence of narrowing is almost never seen until days 3-4 after the initial hemorrhage; the narrowing peaks on days 7-10; within a few weeks vessel diameter returns to baseline [25, 26] . A recent large review [27] identified thick clot burden as the only consistent predictor of subsequent vasospasm.
Intravascular volume depletion has been reported in up to 50% of SAH patients receiving maintenance volumes of fluids [10, 12] . Furthermore, reduced intravascular volume has been associated with the development of clinical symptoms in patients with angiographic vasospasm [12] . Hypervolemic therapy appears to ameliorate the tendency toward intravascular volume contraction [28] .
Previous reports have shown that patients with SAH and vasospasm have an impaired autoregulatory response to changes in CPP [18, 29, 30] . In addition, there is strong evidence associating the loss of normal autoregulatory function with symptomatic vasospasm [13] [14] [15] 31] .
Hemodynamic treatment of delayed ischemic deficits
The use of so called triple-H therapy (hypervolemia, hypertension and hemodilution) stems from numerous clinical observations noting improvement in patients' clinical symptoms of vasospasm following induced hypertension and volume expansion [32] [33] [34] [35] [36] . The relative contributions of each component is debated, although hemodilution appears to improve CBF in response to reduced arterial oxygen content, but does not improve oxygen delivery [37 ] .
Volume expansion
Volume expansion in SAH plays two roles: as a means of preventing or limiting clinical vasospasm and as an acute intervention after the onset of clinical symptoms. Lennihan et al. [38] performed a randomized controlled trial comparing sustained hypervolemia (using boluses of 5% albumin) and euvolemia as a prophylactic treatment for patients with aneurysmal SAH. They found no difference in either regional CBF or rates of vasospasm after 14 days of therapy. Ekelund et al. [39] found no increase in CBF with prophylactic hypervolemia. In contrast, in a series of euvolemic patients with clinical vasospasm (pulmonary capillary wedge pressure >8 mm Hg), acute volume expansion with normal saline raised CBF in the regions of the brain most vulnerable to ischemia [40] .
The clinical effectiveness of volume expansion and hemodynamic augmentation in treating cerebral vasospasm has been explained physiologically by increased CBF in response to increased CPP [18, 20, 41] .
Induced hypertension
Hypervolemia and induced hypertension were the first therapies to be advocated for use in patients with SAHinduced vasospasm. Kosnick and Hunt [32] as well as Kassell et al. [34] reported improvement in neurological status in patients treated with volume expansion, hemodilution and induced hypertension (triple-H therapy). Muizelaar and Becker [42] reported a beneficial effect of phenylephrine on CBF and clinical status in four patients with symptomatic vasospasm.
Cardiac output augmentation
Under normal conditions, changes in cardiac output are not thought to have an important impact on CBF. There is growing clinical and experimental evidence, however, that under abnormal conditions (cerebral ischemia, impaired autoregulation) changes in cardiac output can alter CBF [43] [44] [45] and augmentation of cardiac output with inotropic agents may be effective in treating DID [46] [47] [48] . In five patients with angiographic vasospasm, dobutamine raised cardiac index from 4.1 to 6 l/min/m 2 , and CBF increased without a substantial change in mean blood pressure [48] .
Hemodilution
Hemodilution is perhaps the most controversial component of triple-H therapy. The rationale behind this therapy is to improve blood viscosity in order to augment cerebral perfusion [49] . In a recent retrospective study, however, those patients with higher admission and mean hemoglobin levels after SAH had better outcomes [50 ] ; these findings warrant further investigation.
Rationale for cerebral perfusion pressure therapy in traumatic brain injury
The roles of elevated ICP and ischemia in secondary injury following TBI are incompletely understood. Originally, ICP was the only available parameter for monitoring cerebral function in TBI patients, and our observations were limited to measurements of blood pressure, ICP and CPP. Later, methods to measure CBF became available to clinical investigators, who reported low CBF early after injury. Low CBF was assumed to represent ischemia, and management focused on optimizing ICP and blood pressure to improve CBF. More recent observations have begun to question the role of ischemia in TBI. They suggest that the impaired mitochondrial function rather than ischemia might explain low CBF. Pending further investigation, which may suggest alternative strategies for management of TBI patients, the currently accepted standard in the US focuses on optimizing CBF by treating intracranial hypertension and, if necessary, raising blood pressure to maintain CPP above a 'critical' threshold. Of note, the approach promoted by clinicians in Lund, Sweden, still emphasizes fluid restriction and concern about cerebral swelling with higher CPP and focuses mainly on ICP management [51] .
The rationale for CPP-directed therapy is that a critical reduction in CPP will lead to global cerebral ischemia; therefore, the goal of CPP therapy is to maintain perfusion pressure above this threshold regardless of the ICP. When blood pressure is low or ICP is high and refractory to conventional ICP-lowering therapy, fluids and vasopressors are used to raise blood pressure and thus CPP.
Physiologic studies performed over 25 years ago found hemispheric CBF to be moderately reduced in most patients 1-2 days after TBI [52, 53] ; while others reported hyperemic hemispheric flow in over 50% of patients tested within 96 h of trauma [53] . More recent studies carried out during the first few hours after injury have found hemispheric CBF to be low in most cases [54, 55] . In measurements performed an average of 3.1 h after injury, Bouma and co-workers found CBF below 18 ml/100 g/min (considered to be a critical level for ischemic damage) in one-third of patients [55] . Subsequent reports, which included patients with mass lesions [56] , also demonstrated regional CBF below this threshold in almost 30% of patients studied within 4 h, and in 20% of patients studied 4-8 h after injury.
Yet, reduced CBF alone is inadequate to define ischemia, since it does not take into account the metabolic demands [57] [58] [59] . Some index of metabolic rate or oxygen extraction is also necessary to detect ischemia. The a-vDO 2 has been used to detect global ischemia in TBI; its normal values range from approximately 4.5 to 9 volume% [60] [61] [62] . In a large series, Obrist et al. [63] found evidence of ischemia (defined as a-vDO 2 above 10 volume%) in only one of 75 patients with TBI. Similarly, PET studies in acute TBI patients detect low oxygen extraction, making ischemia unlikely [58, 59] .
Recently, a number of studies suggested an alternative explanation for reduced CBF following TBI. There is a growing body of evidence that following TBI, SAH [19] and intracerebral hemorrhage [64] , metabolic suppression may be the primary event and this is followed by a passive fall in CBF. Using a number of experimental models of TBI, investigators have found impaired mitochondrial function [65] [66] [67] [68] , which results in diminished ATP production. Preliminary PET studies in TBI patients have suggested that there may be a compensatory rise in glucose utilization [69] . Recently, biopsies from a small series of patients with severe TBI also demonstrated impaired mitochondrial function, and some researchers have proposed that mitochondrial function may be used as an intermediate outcome measure for preclinical studies of head injury [69] .
Cerebral perfusion pressure management in traumatic brain injury
A number of prospective trials have investigated the safe threshold for CPP goal after brain trauma [70] [71] [72] [73] [74] [75] [76] [77] [78] addressing either cerebral oxygenation [71] [72] [73] [74] or outcome [70, [76] [77] [78] . A CPP of 60 mmHg appears to provide adequate cerebral perfusion, but regional ischemia may still occur. Even though keeping CPP above 70 mmHg logically seems to be beneficial for cerebral perfusion and is recommended by the Brain Trauma Foundation Guidelines [79] , no improvement in neurologic outcome was demonstrated in clinical studies [75, 80] . Moreover, those patients with higher CPP had an increased incidence of adult respiratory distress syndrome that was thought to be related to induced hypertension [75] .
As in hemodynamic augmentation applied to patients with SAH-related vasospasm, fluids and vasopressors are used to keep CPP at 60 mmHg in TBI victims.
Fluid management
Since both hypovolemia and hypoosmolarity are detrimental in TBI [81, 82, 83 ], an effort should be made to keep patients normovolemic and to avoid excessive hypotonic fluids. Various concentrations of hypertonic saline have been successfully used to reduce cerebral edema and improve cerebral blood flow in experimental studies [84, 85] as well as in clinical practice [86] [87] [88] [89] .
Vasopressors
Vasopressors are widely used to augment blood pressure and therefore, cerebral perfusion. No randomized controlled studies have been performed to compare various pressors in TBI, their benefits, risks or impact on neurologic outcome. Most trials assessing other modalities of treatment of TBI have used vasopressors to maintain adequate CPP. There is, however, a concern based on experimental data [90] [91] [92] [93] that vasopressors may worsen cerebral edema in the injured brain with lost autoregulation. In two clinical studies [94, 95] , in patients with impaired autoregulation due to brain trauma, ICP was elevated in those treated with vasopressors. Therefore, using higher doses of pressors to target CPP well above 60-70 mmHg should be avoided.
Transfusion or hemodilution
As mentioned, above, hemodilution has been shown to improve blood viscosity and thus augment cerebral perfusion, yet higher hemoglobin levels may improve cerebral oxygen delivery. The recommended practice based on scarce experimental and clinical data is to maintain hematocrit at 30 -35% in head-injured patients [96 ] . It has been a matter of recent interest whether patients with TBI benefit from lower levels of hemoglobin [97, 98 ] . McIntyre et al. [98 ] performed post-hoc analysis of the liberal versus restrictive transfusion strategy in the TBI subgroup of the large randomized controlled Transfusion Requirements in Critical Care (TRICC) trial. Even though the neurologic outcomes were not addressed, both strategies seem to be safe.
The mainstay of management of severe TBI currently includes maintenance of sufficient cerebral perfusion while controlling intracranial hypertension [79] . It has been shown that ICP above 20 mmHg is linked to increased mortality [99] [100] [101] , therefore, isolated targeting of adequate CPP goals without aggressive treatment of elevated ICP seems inappropriate.
It must be recognized that high-dose vasopressors and hypervolemic therapy used in hemodynamic augmentation and CPP-directed therapy entail known risks of systemic complications.
Conclusion
The rationale for hemodynamic manipulation in SAH is based on clear observations of reduced regional CBF leading to inadequate oxygen delivery and ischemic injury. Therapy improves perfusion, reversing cerebral ischemia. In traumatic brain injury the rationale is that elevated ICP and, at times, low blood pressure can critically reduce CPP leading to ischemia. Although recent observations suggest that this may not be the case except with extremely low CPP, current practice is to treat ICP and administer vasopressors to maintain CPP above a minimal level of 60-70 mm Hg.
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